Dickneite G, Schwab W, Schorlemmer H U, Gebert U, Sedlacek H H
Research Laboratories of Behringwerke AG, Marburg/Lahn, F.R.G.
Int J Immunopharmacol. 1991;13(5):541-8. doi: 10.1016/0192-0561(91)90074-h.
The isoxazoline derivative HAB 439 was tested for its enzyme inhibiting potency and was found to be an inhibitor of aminopeptidase B (IC50 = 22.5 micrograms/ml). In further immunopharmacological experiments its efficacy to stimulate cell-mediated immunity was evaluated. HAB 439 was shown to stimulate DTH-reaction against Salmonella typhimurium and Listeria monocytogenes. HAB 439 protected animals against infection by reducing the bacterial load in livers and spleens and by decreasing the mortality rate. Treatment with the antibiotic ampicillin induced a decreased DTH-reaction in mice which was demonstrated to be due to a reduction of the antigen to be presented to the immune system and not to immune suppression. HAB 439 restored the impaired immune response to S. typhimurium and L. monocytogenes in a dose-dependent way. Restoration of DTH was shown to lead to an improvement of protection in ampicillin-treated mice which were challenged with the intracellular bacteria.
对异恶唑啉衍生物HAB 439的酶抑制效力进行了测试,发现它是氨肽酶B的抑制剂(IC50 = 22.5微克/毫升)。在进一步的免疫药理学实验中,评估了其刺激细胞介导免疫的功效。结果表明,HAB 439能刺激针对鼠伤寒沙门氏菌和单核细胞增生李斯特氏菌的迟发型超敏反应(DTH)。HAB 439通过降低肝脏和脾脏中的细菌载量以及降低死亡率来保护动物免受感染。用抗生素氨苄青霉素治疗会导致小鼠的DTH反应降低,这被证明是由于呈递给免疫系统的抗原减少,而非免疫抑制所致。HAB 439以剂量依赖的方式恢复了对鼠伤寒沙门氏菌和单核细胞增生李斯特氏菌受损的免疫反应。DTH的恢复被证明能改善经氨苄青霉素治疗且受到细胞内细菌攻击的小鼠的保护作用。